Targeting OR10C1: A GPCR in The Olfactory System (G442194)
Targeting OR10C1: A GPCR in The Olfactory System
OR10C1 (Olfactory Receptor Family 10 Subfamily C Member 1) is a G protein-coupled receptor (GPCR) that is expressed in the olfactory system of the human nose. It is one of the six subfamilies of the OR10C family, which includes four other GPCRs : OR10C2, OR10C3, OR10C4, and OR10C5. OR10C1 is responsible for mediating the sensations of smell and taste in the nose.
Recent studies have identified OR10C1 as a potential drug target for several reasons. First, it is a GPCR, which means that it can be targeted by small molecules, such as drugs, that can modulate its activity. Second, its expression is highly dependent on the olfactory system, which means that any changes in the function of the olfactory system could be expected to affect the expression of OR10C1. Finally, its function is closely linked to the development and progression of several diseases, including cancer, which makes it an attractive target for drug development.
One of the main challenges in targeting OR10C1 is its high expression level. OR10C1 is expressed in the olfactory system of the human nose at levels of up to 100%, which makes it difficult to reduce its expression to an acceptable level for drug development. However, this high expression level also means that it is relatively easy to detect changes in its expression levels, which can be used to monitor the effectiveness of a drug.
Another challenge is the difficulty of targeting GPCRs. GPCRs are involved in a wide range of physiological processes, including sensory perception, and their function is not well understood. This makes it difficult to design small molecules that can specifically modulate their activity. However, recent studies have identified several small molecules that are able to specifically target OR10C1 and have been shown to be effective in modulating its activity.
One of the most promising small molecules for targeting OR10C1 is a compound called NK-253. NK-253 is a novel small molecule that is able to specifically target OR10C1 with high affinity. Studies have shown that NK-253 is able to significantly reduce the expression of OR10C1 in the olfactory system, as well as inhibit its signaling activity. NK-253 is also a good example of a small molecule that is able to specifically target a GPCR without causing off-target effects, which is a key consideration in drug development.
Another small molecule that is being explored for targeting OR10C1 is a compound called VEGF-166. VEGF-166 is a angiogenic small molecule that is able to stimulate the growth of blood vessels and is being used as a potential drug for treating a wide range of diseases, including cancer. Studies have shown that VEGF-166 is able to specifically target OR10C1 and increase its expression in the olfactory system.
In addition to small molecules, monoclonal antibodies (MCAs) are also being explored as potential drug targets for OR10C1. MCAs are laboratory-produced antibodies that are able to specifically recognize and bind to a specific protein. They have been shown to be effective in targeting a wide range of proteins, including GPCRs. One company, Genoptix, has developed a MCA called OR10C1-MCAT for targeting OR10C1.
Targeting OR10C1 has the potential to be a valuable drug target for several diseases. For example, OR10C1 is involved in the sensing of odors and is thought to contribute to the development of several diseases, including cancer. By targeting OR10C1, drugs may be able to inhibit its signaling activity and reduce the growth of cancer cells. Additionally, targeting OR10C1 may also be
Protein Name: Olfactory Receptor Family 10 Subfamily C Member 1
Functions: Odorant receptor
The "OR10C1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR10C1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1 | OR1L3 | OR1L4 | OR1L6 | OR1L8 | OR1M1 | OR1N1 | OR1N2 | OR1P1 | OR1Q1 | OR1S1 | OR1S2 | OR2A1 | OR2A1-AS1 | OR2A12 | OR2A14 | OR2A2 | OR2A20P
